Chatal J F, Charbonnel B
J Clin Endocrinol Metab. 1985 Oct;61(4):769-72. doi: 10.1210/jcem-61-4-769.
Ninety-nine patients suspected of having pheochromocytoma were studied with [131I]metaiodobenzylguanidine scintigraphy, and 92 of them were studied with computed tomography (CT). In 49 patients, the diagnosis was ruled out; in 3 patients, it remained doubtful; and in 47 patients, it was confirmed. Two patients had tumors that did not secrete epinephrine or norepinephrine, and 45 had secreting pheochromocytomas. In these latter patients, there were 4 false negative [131I]metaiodobenzylguanidine scans, all intraadrenal tumors, and 4 false negative CT scans, 3 extraadrenal and 1 intraadrenal tumors. For about 80% of the patients and/or the tumor sites, both methods were thus in agreement. They were complementary in the remaining 20%. The advantage of scintigraphy is to screen the whole body with high specificity and to locate extra-adrenal sites or metastases of pheochromocytoma with better accuracy than CT. The limits of scintigraphy are the possibility of false negative scans in around 10% of patients, whereas CT visualizes more than 95% of intraadrenal tumors.
对99例疑似嗜铬细胞瘤的患者进行了[131I]间碘苄胍闪烁扫描检查，其中92例还进行了计算机断层扫描（CT）检查。49例患者排除诊断；3例诊断仍存疑问；47例确诊。2例患者的肿瘤不分泌肾上腺素或去甲肾上腺素，45例为分泌型嗜铬细胞瘤。在后者中，[131I]间碘苄胍扫描有4例假阴性，均为肾上腺内肿瘤，CT扫描有4例假阴性，3例为肾上腺外肿瘤，1例为肾上腺内肿瘤。因此，对于约80%的患者和/或肿瘤部位，两种方法结果一致。在其余20%的情况下，两种方法互补。闪烁扫描的优点是能以高特异性对全身进行筛查，且比CT更准确地定位嗜铬细胞瘤的肾上腺外部位或转移灶。闪烁扫描的局限性在于约10%的患者可能出现假阴性扫描，而CT能显示95%以上的肾上腺内肿瘤。
